Estimation of hepatic repercussion in obesity and cardiometabolic risk

  1. Mª Teófila Vicente-Herrero 17
  2. Mª Victoria Ramírez-Iñiguez de la Torre 12
  3. Luisa Capdevila García 13
  4. Ana Victoria Bueno Atkinson 4
  5. Ángel Arturo López González 567
  1. 1 Obesity and work group-Asociación Española de especialistas en Medicina del Trabajo-AEEMT.
  2. 2 Occupational Health and safety Services of Correos, Albacete (Spain).
  3. 3 Occupational Health and safety Services MAPFRE, Valencia (Spain).
  4. 4 Occupational Health Nurse. MAPFRE-UBS Majadahonda. Madrid (Spain).
  5. 5 Occupational Health and safety Services Servei de Salut de les Illes Balears.
  6. 6 University School ADEMA, Palma de Mallorca (Spain).
  7. 7 ADEMA-HEALTH Group of the University Institute of Health Sciences-IUNICS Illes Balears (Spain).
Show affiliations +
Journal:
Academic Journal of Health Sciences: Medicina Balear

ISSN: 2255-0560

Year of publication: 2022

Volume: 37

Issue: 5

Pages: 93-98

Type: Article

DOI: 10.3306/AJHS.2022.37.05.93 DIALNET GOOGLE SCHOLAR lock_openIbdigital editor

Abstract

Introducción: La obesidad es una pandemia mundial con repercusión cardiometabólica y riesgo aumentado en el desarrollo de enfermedad hepática no alcohólica. Es objetivo de este trabajo relacionar el riesgo cardiometabólico en obesidad con el riego de repercusión hepática en población trabajadora. Método: Estudio descriptivo transversal en 815 trabajadores entre marzo de 2020- junio de 2021. Se utilizan las calculadoras FLI- fatty liver index y FIB-4 Index for liver fibrosis y su relación con el índice de masa corporal y el riesgo cardiometabólico. Resultados: Se encontró una mayor presencia de valores altos de FLI y FIB-4 en los grupos con mayor nivel de riesgo cardiometabólico y con IMC en niveles de sobrepeso/obesidad, con resultados más desfavorables en hombres. Conclusiones: En trabajadores con obesidad y riesgo cardiovascular o síndrome metabólico se detecta mayor riesgo de repercusión hepática cuantificada con FLI y FIB-4.

Bibliographic References

  • Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016 Dec;45(4):571-579. doi: 10.1016/j.gtc.2016.07.012.
  • Healthy people 2030. https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity (accessed 2022, March 10,)
  • Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22.
  • Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
  • Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019 Mar;92:98-107. doi: 10.1016/j.metabol.2018.10.011. Epub 2018 Nov 3.
  • Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016 May 27;118(11):1752-70. doi: 10.1161/CIRCRESAHA.115.306883.
  • Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017 Jan 3;127(1):1-4. doi: 10.1172/JCI92035. Epub 2017 Jan 3.
  • Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020 Nov 14;12(11):3501. doi: 10.3390/nu12113501.
  • Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1899-1912. doi: 10.1053/j.gastro.2019.12.054. Epub 2020 Feb 13.
  • Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014 Jul 28;20(28):9330-7. doi: 10.3748/wjg.v20.i28.9330.
  • World Health Organization 2020. Body mass index – BMI. Available at: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. (accessed 2022, March 10)
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, López González AA. Estimación del nivel de riesgo cardiometabólico en trabajadores con sobrepeso/obesidad durante la pandemia Covid-19. Estilo de vida y variables sociodemográficas. [Estimation of cardiometabolic risk in overweight or obese workers during Covid-19 pandemic. Life style and sociodemographic variables] Academic Journal of Health Sciences 2022/37 (3): 134-41.
  • Buitrago Ramírez F, Cañón Barroso L, Díaz Herrera N, Cruces Muro E, Bravo Simón B, Pérez Sánchez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años [Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up]. Med Clin (Barc). 2006 Sep 16;127(10):368-73. Spanish. doi: 10.1157/13092437.
  • Registre Gironí del Cor. Validación de las tablas Framigrahm-Regicor [Validation of Framigrahm-Regicor tables] ;2022 https://regicor.cat/es/presentacion/tablas-de-framingham-regicor/
  • Grau M, Marrugat J. Risk Functions and the Primary Prevention of Cardiovascular Disease. Rev Esp Cardiol. 2008;61(4):404-16.
  • Taberner R. Calculadora multiplataforma para síndrome metabólico y riesgo cardiovascular en pacientes con psoriasis [Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis]. Actas Dermosifiliogr. 2012 Mar;103(2):111-9. Spanish. doi: 10.1016/j.ad.2011.11.003. Epub 2012 Jan 28.
  • Tutunchi H, Ebrahimi Mameghani M, Ostadrahimi A, Asghari Jafarabadi M. What are the optimal cut-off points of anthropometric indexes for prediction of overweight and obesity? Predictive validity of waist circumferemce, waist-to-hip and waist-to-height ratios. Health Promotion Perspectives 2020;10(2)142-7.
  • Bello Chavolla OY, Antonio Vila NE, Vargas Vázquez A, Viveros Ruiz TL, Almeda Valdes P, Gómez Velasco D, et al. Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health. Clin Nutr 2020;39(5):1613-20.
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, Capdevila García L, Partida-Hanon A, Reinoso-Barbero L, López González AA. Prevalence of overweight and obesity in Spanish working population along the Covid-19 pandemic. Adiposity indicators and related variables. Academic Journal of Health Sciences 2022/37 (1): 90-4
  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33. doi: 10.1186/1471-230X-6-33.
  • Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018 Feb;68(2):305-315. doi: 10.1016/j.jhep.2017.11.013. Epub 2017 Dec 2.
  • Ros E. The PREDIMED study. Endocrinol Diabetes Nutr 2017;64(2):63-6.
  • Ferreira-Pêgo C, Nissensohn M, Kavouras SA, Babio N, Serra-Majem L, Martín Águila A, et al. Beverage Intake Assessment Questionnaire: Relative Validity and Repeatability in a Spanish Population with Metabolic Syndrome from the PREDIMED-PLUS Study. Nutrients 2016;8(8):475.
  • Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35(8):1381-95.
  • Román Viñas B, Ribas Barba L, Ngo J, Serra Majem L. Validación en población catalana del cuestionario internacional de actividad física [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. Gac Sanit 2013;27(3):254-7.
  • Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. Eur J Public Health. 2018 Apr 1;28(2):295-300. doi: 10.1093/eurpub/ckx143.
  • Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-319-48382-5_1.
  • Piché ME, Poirier P, Lemieux I, Després JP. Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update. Prog Cardiovasc Dis. 2018 Jul-Aug;61(2):103-113. doi: 10.1016/j.pcad.2018.06.004. Epub 2018 Jun 28.
  • Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci. 2021 Apr 15;271:119220. doi: 10.1016/j.lfs.2021.119220. Epub 2021 Feb 13.
  • Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10(1):63-71. doi: 10.1586/17474124.2016.1099433. Epub 2015 Oct 15.
  • Castera L. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):291-303. doi: 10.1055/s-0035-1562948. Epub 2015 Sep 17.
Data source: Dialnet